• Je něco špatně v tomto záznamu ?

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial

J. Trotman, PL. Zinzani, Y. Song, R. Delarue, P. Kim, E. Ivanova, R. Korde, J. Mayer, AC. De Oliveira, SE. Assouline, CR. Flowers, G. Barnes

. 2024 ; 40 (11) : 1863-1871. [pub] 20241014

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003613

OBJECTIVE: We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior efficacy and a manageable safety profile with zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) in patients with heavily pretreated relapsed/refractory follicular lymphoma (R/R FL). METHODS: PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) and EQ-5D-5L questionnaires at baseline and subsequently every 12 weeks. All QLQ-C30 domains and EQ-5D-5L visual analog scale (VAS) scores were analyzed descriptively. At the key clinical timepoints (weeks 12 and 24), a mixed model for repeated measures (MMRM) analysis was used to evaluate the key PRO endpoints, including global health status, physical and role functioning, and symptoms of fatigue, pain, diarrhea, and nausea/vomiting. Clinically meaningful change was defined as a ≥ 5-point mean difference from baseline and between the ZO and O arms. RESULTS: Patients were randomized to ZO (n = 145) or O (n = 72). By week 48, descriptive analysis results indicated that patients in the ZO arm demonstrated improved outcomes in role functioning and fatigue and nausea/vomiting symptoms, compared with those in the O arm. Both groups experienced improvements in pain symptoms. EQ-5D-5L VAS scores showed no observable differences between treatment arms through week 48. MMRM analysis revealed that the global health status/quality of life of patients treated with ZO improved, as did fatigue, at week 12. At week 24, patients in the ZO arm experienced a clinically meaningful improvement in role functioning, pain, and fatigue. CONCLUSIONS: In patients with R/R FL, ZO was associated with improved PROs compared with O. These findings suggest that zanubrutinib contributed clinically meaningful benefits to patient HRQoL when added to obinutuzumab. TRIAL REGISTRATION: The ROSEWOOD trial is registered on ClinicalTrials.gov (BGB-3111-212; ClinicalTrials.gov identifier: NCT03332017).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003613
003      
CZ-PrNML
005      
20250206104442.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2024.2409837 $2 doi
035    __
$a (PubMed)39376156
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trotman, Judith $u Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
245    10
$a Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial / $c J. Trotman, PL. Zinzani, Y. Song, R. Delarue, P. Kim, E. Ivanova, R. Korde, J. Mayer, AC. De Oliveira, SE. Assouline, CR. Flowers, G. Barnes
520    9_
$a OBJECTIVE: We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior efficacy and a manageable safety profile with zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) in patients with heavily pretreated relapsed/refractory follicular lymphoma (R/R FL). METHODS: PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) and EQ-5D-5L questionnaires at baseline and subsequently every 12 weeks. All QLQ-C30 domains and EQ-5D-5L visual analog scale (VAS) scores were analyzed descriptively. At the key clinical timepoints (weeks 12 and 24), a mixed model for repeated measures (MMRM) analysis was used to evaluate the key PRO endpoints, including global health status, physical and role functioning, and symptoms of fatigue, pain, diarrhea, and nausea/vomiting. Clinically meaningful change was defined as a ≥ 5-point mean difference from baseline and between the ZO and O arms. RESULTS: Patients were randomized to ZO (n = 145) or O (n = 72). By week 48, descriptive analysis results indicated that patients in the ZO arm demonstrated improved outcomes in role functioning and fatigue and nausea/vomiting symptoms, compared with those in the O arm. Both groups experienced improvements in pain symptoms. EQ-5D-5L VAS scores showed no observable differences between treatment arms through week 48. MMRM analysis revealed that the global health status/quality of life of patients treated with ZO improved, as did fatigue, at week 12. At week 24, patients in the ZO arm experienced a clinically meaningful improvement in role functioning, pain, and fatigue. CONCLUSIONS: In patients with R/R FL, ZO was associated with improved PROs compared with O. These findings suggest that zanubrutinib contributed clinically meaningful benefits to patient HRQoL when added to obinutuzumab. TRIAL REGISTRATION: The ROSEWOOD trial is registered on ClinicalTrials.gov (BGB-3111-212; ClinicalTrials.gov identifier: NCT03332017).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D000971
650    12
$a folikulární lymfom $x farmakoterapie $7 D008224
650    12
$a hodnocení výsledků péče pacientem $7 D000071066
650    12
$a pyrazoly $x aplikace a dávkování $x terapeutické užití $7 D011720
650    12
$a pyrimidiny $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D011743
650    12
$a kvalita života $7 D011788
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Zinzani, Pier Luigi $u IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
700    1_
$a Song, Yuqin $u Peking University Cancer Hospital and Institute, Beijing, China
700    1_
$a Delarue, Richard $u BeiGene Switzerland GmbH, Basel, Switzerland
700    1_
$a Kim, Pil $u BeiGene USA, Inc., San Mateo, CA, USA
700    1_
$a Ivanova, Elena $u BeiGene (Shanghai) Co., Ltd., Shanghai, China
700    1_
$a Korde, Rasika $u BeiGene USA, Inc., San Mateo, CA, USA
700    1_
$a Mayer, Jiří $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czechia
700    1_
$a De Oliveira, Ana C $u Institut Catala d'Oncologia (ICO), Hospital Duran I Reynals, Barcelona, Spain
700    1_
$a Assouline, Sarit E $u Jewish General Hospital, McGill University, Montreal, QC, Canada
700    1_
$a Flowers, Christopher R $u Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA
700    1_
$a Barnes, Gisoo $u BeiGene USA, Inc., San Mateo, CA, USA
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 40, č. 11 (2024), s. 1863-1871
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39376156 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104437 $b ABA008
999    __
$a ok $b bmc $g 2263390 $s 1239620
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 40 $c 11 $d 1863-1871 $e 20241014 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace